Amgen Inc.'s plan to buy out nephrology-focused Ilypsa Inc. for $420 million - thereby gaining a Phase II phosphate binder for chronic kidney disease - put little immediate fear into backers of Genzyme Corp., thanks to progress with the latter's CKD therapy Renvela. (BioWorld Today)
About a week after AtheroGenics Inc. disclosed in SEC paperwork that the firm is saying goodbye to about half its work force, and slightly more than a month after partner AstraZeneca plc bailed out of a major deal for AGI-1067, the Phase III focus for that compound is shifting from atherosclerosis to diabetes. (BioWorld Today)
Iomai Corp.'s Phase I flop with its influenza-vaccine patch knocked shares down 40 percent, and sent researchers back to the drawing board - armed, at least, with data that their adjuvant to the vaccine, called LT, helped response. (BioWorld Today)
